Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats

Irene Sáez-Torres, C. Espejo, J. J. Pérez, N. Acarín, X. Montalban, E. M. Martínez-Cáceres

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL-4 and interferon-gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats.
Original languageEnglish
Pages (from-to)151-156
JournalClinical and Experimental Immunology
Volume121
DOIs
Publication statusPublished - 17 Jul 2000

Keywords

  • Experimental autoimmune encephalomyelitis
  • Lewis rat
  • Multiple sclerosis
  • Peptide T

Fingerprint Dive into the research topics of 'Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats'. Together they form a unique fingerprint.

  • Cite this